In patients with melanoma treated with anti-programmed cell death protein 1 (OS, HR, 0.61; 95%CI, 0.51-0.72; <i>P</i><0.00001; PFS, HR, 0.59; 95%CI, 0.47-0.74; <i>P</i><0.00001), the association between irAEs and clinical benefit was clearer than in patients treated with anti-cytotoxic T-lymphocyte-associated protein 4 (OS, HR, 0.68; 95%CI, 0.52-0.89; <i>P</i>=0.005; PFS, HR, 0.93; 95%CI, 0.49-1.78; <i>P</i>=0.83).<h4>Conclusion</h4>Among patients with melanoma treated with ICIs, those who developed non-thyroid endocrine irAEs and cutaneous irAEs have better prognosis. The gene discussed is CTLA4; the disease is melanoma.